EUCTR2018-002430-21-DE进行中（未招募）1 期
Primary comparison of Liposomal Anthracycline based treatment versus conventional care strategies prior to allogeneic stem cell transplantation in patients with higher risk MDS and oligoblastic AML - PALOMA
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- GWT-TUD GmbH
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Adult patients, 18-75 years of age
- •2. Diagnosis of high risk MDS including oligoblastic non-proliferative (WBC <13 Gpt/l) AML up to 29% of bone marrow blasts
- •3. Bone marrow blasts = 5% (central morphology Düsseldorf)
- •4. IPSS score intermediate-2 or high
- •5. alloHCT intended within the next 6 months
- •6. ECOG performance status of 0 or 1
- •7. Signed informed consent
- •8. Laboratory values fulfilling all of the following:
- •- Serum creatinine < 2.0 mg/dL
- •- Serum total bilirubin < 2.0 mg/dL
- •- Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN
- •9. Cardiac ejection fraction (LVEF) = 50% by echocardiography
- •10. Contraception:
- •- Female subjects of childbearing potential† must agree to use a medically acceptable method of contraception from signature of ICF (for at least 1 months prior to the first dose of CPX-351) and consent of female patients to use a medically acceptable method of contraception throughout the entire study period and for 6 months following the last dose of CPX-351. Medically acceptable methods of contraception that may be used by the patient include diaphragm and spermicide, intrauterine device (IUD), condom and vaginal spermicide, hormonal contraceptives (patients must be stable on hormonal contraceptives for at least the prior 3 months), surgical sterilization, or post-menopausal (=2 years of amenorrhea). Medically acceptable methods of contraception that may be used by the male partner of a female patient are condom and spermicide or vasectomy (>6 months prior to Day-1) and are to be used throughout the entire study period and for 6 months following the last dose of CPX-351.
- •- Male patients must be willing to refrain from sperm donation for 6 months following the last dose of CPX-351 and must use adequate contraception throughout the entire study period and for 6 months following the last dose of CPX-351.
- •- Combined oral contraceptive pills are not recommended. It is recommended that during the study two medically accepted methods of contraception (e.g. as hormonal contraceptive methods along with a condom) apply.
- •†A female subject or a female partner of a male subject is considered to have childbearing potential unless she meets at least one of the following criteria: Age =50 years and naturally amenorrhoeic for = 1 year (amenorrhoea following cancer therapy does not rule out childbearing potential), premature ovarian failure confirmed by a specialist gynecologist, previous bilateral salpingo-oophorectomy or hysterectomy, XY genotype, Turner syndrome or uterine agenesis.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 135
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1. Patients with history of myeloproliferative neoplasms (MPN) (defined as a history of essential thrombocytosis or polycythemia vera, or idiopathic myelofibrosis prior to the diagnosis of AML) or combined MDS/MPN are not eligible.
- •2. WHO-2016 defined AML entities: AML with t(15;17), PML-RARA; AML with t(8;21), RUNX1-RUNX1T1, AML with inv(16)/t(16;16), CBFß-MYH11; AML with BCR-ABL1, AML with biallelic CEBPA mutation; AML with mutated FLT3 or NPM1.
- •3. Clinical evidence of active CNS leukaemia (assessment of CSF is not mandatory for screening).
- •4. Patients with a currently active” second malignancy other than non-melanoma skin cancers. Patients are not considered to have a currently active” malignancy if they have completed therapy more than 2 years ago and are disease free.
- •5. Any major surgery or radiation therapy within four weeks prior screening.
- •6. Patients with prior treatment of either CPX-351, hypomethylating agents, cytarabine or intensive chemotherapy for high-risk MDS or AML.
- •7. Patients with prior cumulative anthracycline exposure of greater than 368 mg/m2 daunorubicin (or equivalent).
- •8. Recent (<30 days) or planned live vaccinations during the clinical trial
- •9. Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent obtaining informed consent.
- •10. Creatinine clearance < 30 ml/min
- •11. Active or uncontrolled infection. Patients with an infection receiving treatment (antibiotic, antifungal or antiviral treatment) may be entered into the study but must be afebrile and hemodynamically stable for =72 hrs.
- •12. Current evidence of invasive fungal infection (blood or tissue culture); patients with recent fungal infection must have a subsequent negative cultures to be eligible; known HIV (new testing not required) or evidence of active hepatitis B or C infection (with rising transaminase values).
- •13. Hypersensitivity to cytarabine, daunorubicin or liposomal products.
- •14. History of Wilson’s disease or other copper-metabolism disorder, unless the therapy outweighs the risks.
- •15. Female patients who are pregnant or lactating.
研究者
相似试验
进行中（未招募）
1 期
Primary comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AMntreated patients with higher risk MDS and oligoblastic AML eligible and intended for allogeneic HCT within the next 6 monthsMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2018-002430-21-ATGWT-TUD GmbH20
招募中
2 期
A clinical study conducted to evaluate the safety, efficacy and tolerability of a drug called liposomal annamycin administered with cytarabine, in patients with acute myeloid leukemia.Acute Myeloid Leukemia2024-516388-10-00Moleculin Biotech Inc.24
招募中
1 期
Study to evaluate the optimal dose and efficacy of a new drug called L-Annamycin in combination with cytarabine in patients suffering from Acute Myeloid Leukemia that has come back after a previous treatmentMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864Acute Myeloid LeukemiaEUCTR2020-005493-10-ITMoleculin Biotech, Inc.63
进行中（未招募）
不适用
Reinduction with liposomal anthracyclines and Capecitabine in patients with breast cancer, locally advanced (IIIA-IIIB-IIIC) HER2 negative, not obtaining a pathological complete response (<PCR) after primary chemotherapy. - ICARO 2Population of female patients suffering from breast cancer in initial clinical stage IIIA, IIIB and IIIC not expressing HER2 and who have not obtained a pathological complete response (defined <PCR) after neoadjuvant chemotherapyMedDRA version: 12.0Level: LLTClassification code 10006283Term: Breast neoplasm malignant femaleEUCTR2009-011756-22-ITAZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
已完成
4 期
Comparison study of liposomal amphotericin B and micafungin in treatment of deep candidasis in surgical and emergency domainsInvasive CandidiasisJPRN-UMIN000006106Department of Infection Control and Prevention, Aichi Medical University Hospital100